At the pathway level, we observed a consistent positive enrichment in pathways related to differentiation, NF-κB signaling, and pathways relevant to tumor-immune cross-talk (IL-10 signaling, cytokine receptor interaction) (Figure 2C) and negative enrichment in multiple pathways, including eukaryotic protein elongation and ribosome pathways (Figure 2D). This evidence concerns the gene NFKB1 and neoplasm.